Synaptopodin Antibodies

Synaptopodin (SYNPO)

Actin-associated protein which may play a role in regulating actin-based shape and motility of dendritic spines and renal podocyte foot processes. Appears to be essential for the formation of spine apparatuses in spines of telencephalic neurons, which is involved in synaptic plasticity (By similarity).

. .

Gene Information

Human
Gene Name:	SYNPO
Uniprot:	Q8N3V7
Entrez:	11346

Family

Belongs to:
synaptopodin family

Alternative Names

KIAA1029; Synaptopodin; SYNPO

Molecular Weight

Mass (kDA):
99.463 kDA

Genomic Context

Human
Location:	5q33.1
Sequence:	5; NC_000005.10 (150586026..150659214)

Tissue Specificity

Expressed in cerebral cortex.

Subcellular Localizations

Cytoplasm, cytoskeleton. Cell junction, tight junction. Perikaryon. Cell projection, dendritic spine. Cell junction, synapse, postsynaptic density. Cell junction, synapse. Cytoplasm, cytosol. Localized at the tight junction of cells. In brain, localized to the postsynaptic densities and in the perikarya. Associated with dendritic spines of a subset of synapses.

Diseases

• Kidney Diseases
• Proteinuria Of Undiagnosed Cause
• Glomerulosclerosis (disorder)
• Focal Glomerulosclerosis
• Neoplasms
• Segmental Glomerulosclerosis
• Diabetic Nephropathy
• Aids-associated Nephropathy
• Sclerosis
• Nephrotic Syndrome
• Renal Glomerular Disease
• Nephroblastoma
• Glomerulonephritis

• Anaplasia
• Diabetes Mellitus
• Glomerulonephritis, Minimal Change
• Kidney Failure, Chronic
• Kidney Failure
• Macular Corneal Dystrophy Type I
• Hyperplasia

Interacting Proteins

• ACTN1

Pathways

• Pathogenesis
• Localization
• Glomerular Filtration
• Dedifferentiation
• Excretion
• Gene Silencing
• Cell Migration
• Cell Cycle
• Cell Proliferation
• Transport
• Cell Division
• Membrane Depolarization
• Cell Motility

• Regulation Of Synaptic Plasticity
• Cell Adhesion
• Neurogenesis
• Tropism
• Nuclear Export
• Cell Cycle Arrest
• Inflammatory Response

PTMs

• Phosphorylation
• Cleavage

• Ubiquitination
• Dephosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SYNPO

Boster Bio Anti-Synaptopodin/SYNPO Antibody

If you're interested in learning about the Boster Bio Anti-Synaptopodin/SYNPO Antibody, you've come to the right place. This article will describe the mechanism of this antibody and its clinical uses. Then, read the reference material to learn about Boster Bio's exclusive technology. This technology uses primary antibodies that have been validated by ELISA, Western Blotting, and Immunohistochemistry.

Boster Bio Anti-Synaptopodin/SYNPO Antibody

This anti-Synaptopodin/anti-Synaptopodin antibody reacts with Mouse and Human Synaptopodin. It is available in 0.02 percent sodium azide PB. The antibody is raised against a synthetic peptide corresponding to amino acids 320-370 in human SYNPO2. For specific lengths blocking peptides are offered separately.

The boster bio anti-Synaptopodin/synaptoprotein antibody is a highly specific and quantitative ELISA kit. This antibody is highly sensitive and has been tested for IHC and ELISA applications. Boster Bio antibodies have been tested against a panel of 250 tissue samples. The antibodies were tested both qualitatively and quantitatively on cell lines that have known amounts of recombinant protein.

Synaptopodin (or SYNPO) is an actin-binding protein that is found in a specialized type ER called the spine apparatus. The spine apparatus consists of a series of stacked discs connected to dendritic tubules that are ER-related. Synaptopodin was first discovered in podocytes in the kidney. Synaptopodin isn't formed in mice. The spine apparatus is vital to memory and learning and its absence impairs the formation of these structures.

Clinical Applications

Since decades since the SYNPO marker has been utilized in kidney disease biomarkers. Recent research has linked this gene with FSGS and other renal disorders. These studies suggest that heterozygous mutation carriers are associated with poorer clinical outcomes, including end-stage renal failure. There are still many questions regarding the clinical relevance and the efficacy of SYNPO in FSGS diagnosis. This article summarizes many of these questions and outlines the latest research.

In this study, functional effects of SYNPO promoter mutations in the gene were studied using the ACTN4 reporter gene and podocytes. The mutations 1-1044delT and 1-851C decreased the expression of luciferase in PC12 cells, while the variants were able to produce 50% lower levels of Luciferase. This is a promising method for assessing SYNPO expression in kidney cancer, and could be used to identify kidney disease.

The peripheral leukocytes as well as hair foollicles were used to identify the SYNPO gene. The promoter sequences were identified from genomic DNA of mononuclear cells. Then, cDNA was synthesized with a ReverTra Ace kit. qPCR was performed with the SYBR Green qPCR kit. The genes SYNPO and GAPDH were found as well as NPHS2 and reverse 5' NPHS2 served as reference genes.

The SYNPO gene promoter was altered in three patients. The mutations that affect ACTN4 gene did not appear in the controls nor in the parents of the patients. One patient suffering from a SYNPO gene promoter mutation had decreased synaptopodin expression, whereas the kidney of the other patient was normal. This finding suggests that SYNPO gene promor mutations are common in kidney diseases. It could be due to a defect in proteinuria regulation.

Refer to

To determine the expression level of the SYNPO marker We first looked at its structure. By using the NCBI reference sequence database, we retrieved the cDNA ORF sequences of SYNPO. Each cDNA ORF sequence represents a portion of the SYNPO gene that encodes the protein. Our SYNPO gene clones were delivered in pcDNA3.1+/C-(K)DYK, a standard vector. To obtain a more detailed analysis, we also designed an individual vector for this marker.